Press release

DocMorris and apo-rot cooperate

- Mail order business is transferred to the Netherlands

- Expansion of the Omni-Channel concept

- Zur Rose Group expands its leading market position in Europe

The pharmacy DocMorris is cooperating with omnichannel pharmacy apo-rot, based in Hamburg, and will in future operate its mail order business autonomously from the Netherlands. In addition, DocMorris and apo-rot will jointly expand the existing omnichannel concept as part of a strategic collaboration and further develop its content.

Under its founder and owner, Birgit Dumke, apo-rot has grown over 15 years to become one of the top five mail order pharmacies in Germany. Apo-rot is also represented internationally in markets such as Denmark and Austria. The mail order pharmacy, which focuses on over-the-counter medicines, achieved sales of around EUR 100 million in 2017 with more than 780,000 active customers.

By combining the strengths of both partners, apo-rot's cross-channel pharmacy model and shipping activities will be put on a broader footing in the future. The innovative connection between mail order and on-site pharmacies is the key for all parties involved to greater quality and safety for the individual patient.

In Germany, apo-rot will continue to be successfully positioned in the future with four own pharmacies and 18 partner pharmacies. On this basis, online market leader DocMorris and apo-rot will collaborate to promote digital transformation under the keyword "pharmacy 4.0". Among other things, the "Click & Collect" model, which already exists at apo-rot and its partner pharmacies, will be continued and later extended to the entire DocMorris customer base. In the field of medication management, an electronic medication plan will be jointly introduced.

The employees of the successful marketing and service team of apo-rot will remain at their current location in Hamburg. DocMorris intends to combine and coordinate logistics at its location in Heerlen at the end of 2018 in order to generate synergy effects. With this next strategic step, the Zur Rose Group is continuing to consolidate its position in Germany as the largest European mail order market and systematically expanding its leading market position in Europe. With apo-rot, another strong brand complements the existing portfolio in the German market. The transaction is subject to approval by the relevant competition authorities and was supported by Ferber & Co. GmbH. Both have agreed to maintain confidentiality about the financial aspects.

Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail: ir@zurrose.com, telephone: +41 52 724 00 64

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail: lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Agenda
24 May 2018 Annual General Meeting
15 August 2018 Half-year report (analyst and media conference)
24 October 2018 Q3 Trading Update

Zur Rose Group

Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.

The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.